Detailed information about our clinical trials is provided through independent registries such as and EUdraCT.

Trial Description: Safety, feasibility and pharmacokinetic study to confirm that the recommended safe dose and schedule of ModraDoc006/r (oral docetaxel with ritonavir) as determined in a previous Phase I study is also safe and feasible in the target population of patients with metastatic castration-resistant prostate cancer
Phase: II
Status: Active, recruiting
Disease: Metastatic castration-resistant prostate cancer
Information: NCT03136640
Trial Description: Study to evaluate the effect of food on the pharmacokinetics of ModraDoc006 in combination with ritonavir, in an open-label, cross-over design. Patients will be randomized into two treatment groups receiving ModraDoc006/r week 1 under fasting and week 2 under fed condition, or vice versa
Phase: I
Status: Active, recruiting
Disease: Solid tumors
Information: NCT03147378



Phase I results with ModraDoc006/r published in the European Journal of Cancer
Read more

the IV to Oral switch

improving patient lives
Learn more


Meet us at one of the following events:      
Read more